Vitamin D and multiple sclerosis: Can vitamin D prevent disease progression?

Expert Review of Neurotherapeutics

Volumn 11, Issue 4, 2011, Pages 469-471

  Mehta, Bijal ^a   Ramanathan, Murali ^a   Weinstock Guttman, Bianca ^a  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

cytokines; disease progression; experimental acute encephalomyelitis; Kurtzke EDSS; multiple sclerosis; VDR; vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; PARATHYROID HORMONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; B LYMPHOCYTE; BONE MINERALIZATION; BRAIN ATROPHY; CALCIUM INTAKE; CELL DIFFERENTIATION; CLINICAL EVALUATION; CLINICAL STUDY; CYTOKINE RELEASE; DIET RESTRICTION; DISABILITY; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; EXPANDED DISABILITY STATUS SCALE; FALLING; FRACTURE; GENE REGULATORY NETWORK; GENETIC PREDISPOSITION; HOMEOSTASIS; HUMAN; HYGIENE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY INJURY; LATITUDE; MODULATION; MONOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; OSTEOPOROSIS; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PROTEIN EXPRESSION; REGULATOR GENE; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; SUN EXPOSURE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TISSUE INJURY; TREATMENT DURATION; VIRUS INFECTION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; RECURRENCE; RISK FACTORS; VITAMIN D; VITAMINS;

EID: 79953748215     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.44     Document Type: Review

References (31)

1. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr. Scand. 35(Suppl. 147), 132-147 (1960).
2. Kurtzke JF. Geography in multiple sclerosis. J. Neurol. 215(1) 1-26 (1977). (Pubitemid 8082347)
3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun. Rev. 9(5), A387-A394 (2010).
4. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 216, 21-27 (1997).
5. Carlyle IP. Multiple sclerosis: a geographical hypothesis. Med. Hypotheses 49, 477-486 (1997). (Pubitemid 28009182)
6. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1), 60-65 (2004). (Pubitemid 38082871)
7. Kragt JJ, van Amerongen BM, Killestein J et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler. 15, 9-15 (2009).
8. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23), 2832-2838 (2006). (Pubitemid 44969183)
9. Marie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. (12), 709-718 (2004).
10. Hutter CD, Laing P. Multiple sclerosis: sunlight, diet, immunology and aetiology. Med. Hypotheses 46(2), 67-74 (1996). (Pubitemid 26075766)
11. Brahic M. Multiple sclerosis and viruses. Ann. Neurol. 68(1), 6-8 (2010)
12. Leibowitz U, Atonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J. Neurol. Neurosurg. Psychiatry 29, 60-68 (1966).
13. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium, and vitamin D. Med. Hypotheses 21(2), 193-200 (1986). (Pubitemid 17201931)
14. Smolders J. Vitamin D and multiple sclerosis: correlation, causality, and controversy. Autoimmune Dis. 2011, 629538 (2010)
15. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26, 662-687 (2005). (Pubitemid 41127276)
16. Lemire JM, Clay Archer D. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87, 1103-1107 (1991).
17. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunology 194(1-2), 7-17 (2008).
18. Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J. Biol. Chem. 285(50), 38751-38755 (2010).
19. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 134(1-2), 128-132 (2003). (Pubitemid 36050838)
20. Smolders J, Thewissen M, Peelen E et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 4(8), e6635 (2009).
21. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 132(Pt 5), 1146-1160 (2009).
22. Simpson S Jr, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann. Neurol. 68(2), 193-203 (2010).
23. Mowry EM, Krupp LB, Milazzo M et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann. Neurol. 67, 618-624 (2010).
24. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11, 266-271 (2005). (Pubitemid 40775180)
25. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 14, 1220-1224 (2008).
26. van der Mei IA, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 254(5), 581-590 (2007). (Pubitemid 46781963)
27. Weinstock-Guttman B, Zivadinov R, Qu J et al. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J. Neurol. Neurosurg. Psychiatry 82(2), 189-195 (2011).
28. Wingerchuk DM. Lesaux J. Rice GP. Kremenchutzky M. Ebers GC. A pilot study of oral calcitriol (1, 25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76(9), 1294-1296 (2005). (Pubitemid 41208389)
29. Burton JM, Kimball S, Vieth R et al. A Phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74(23), 1852-1859 (2010).
30. Consensus Report. Dietary Reference Intakes for Calcium and Vitamin D. Food and Nutrition Board, Institute of Nutrition, DC, USA (2010).
31. Weinstock-Guttman B, Gallagher E, Baier M et al. Risk of bone loss in men with multiple sclerosis. Mult. Scler. 10(2), 170-175 (2004). (Pubitemid 38499910)